Evidence map›Paper›PMID 41620502›Full record

ArticleScientific reports2026

Staphylococcus capitis strain producing dual bacteriocins, capidermicin and micrococcin P1, shows broad-spectrum antimicrobial activity.

Keijuro Ohdan, Yujin Suzuki, Miki Kawada-Matsuo, Toshinori Hara, Mi Nguyen-Tra Le, Takaya Segawa, Junzo Hisatsune, Yo Sugawara, Seiya Kashiyama, Hiroki Ohge and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Keijuro OhdanDepartment of Oral and Maxillofacial surgery, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan.
Yujin SuzukiDepartment of Bacteriology, Hiroshima University Graduate School of Biomedical and Health Sciences, 1-2-3 Kasumi, Minami-ku, Hiroshima-shi, Hiroshima Prefecture, 734-8551, Japan.
Miki Kawada-MatsuoDepartment of Bacteriology, Hiroshima University Graduate School of Biomedical and Health Sciences, 1-2-3 Kasumi, Minami-ku, Hiroshima-shi, Hiroshima Prefecture, 734-8551, Japan. mmatsuo@hiroshima-u.ac.jp.
Toshinori HaraSection of Clinical Laboratory, Division of Clinical Support, Hiroshima University Hospital, Hiroshima, Japan.
Mi Nguyen-Tra LeFaculty of Dentistry, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam.
Takaya SegawaAntimicrobial Resistance Research Center, National Institute of Infectious Diseases, Japan Institute for Health Security, Higashi Murayama, Japan.
Junzo HisatsuneAntimicrobial Resistance Research Center, National Institute of Infectious Diseases, Japan Institute for Health Security, Higashi Murayama, Japan.
Yo SugawaraAntimicrobial Resistance Research Center, National Institute of Infectious Diseases, Japan Institute for Health Security, Higashi Murayama, Japan.
Seiya KashiyamaSection of Clinical Laboratory, Division of Clinical Support, Hiroshima University Hospital, Hiroshima, Japan.
Hiroki OhgeProject Research Centre for Nosocomial Infectious Diseases, Hiroshima University, Hiroshima, Japan.
Motoyuki SugaiAntimicrobial Resistance Research Center, National Institute of Infectious Diseases, Japan Institute for Health Security, Higashi Murayama, Japan.
Tomonao AikawaDepartment of Oral and Maxillofacial surgery, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan.
Hitoshi KomatsuzawaDepartment of Bacteriology, Hiroshima University Graduate School of Biomedical and Health Sciences, 1-2-3 Kasumi, Minami-ku, Hiroshima-shi, Hiroshima Prefecture, 734-8551, Japan. komatsuz@hiroshima-u.ac.jp.

Funding

Grant-in-Aid for Scientific Research (C) Grant No. 21K12886the Japan Agency for Medical Research and Development (AMED) JP23fk0108606 and JP25fk0108699
6 · The paper itself

Abstract

Antimicrobial-resistant bacteria have become a global concern, necessitating the development of novel antimicrobial agents. Bacteriocins, antimicrobial peptides produced by bacteria, are promising candidates. In this study, we screened Staphylococcus capitis isolates to identify bacteriocins effective against methicillin-resistant Staphylococcus aureus (MRSA). We discovered that one strain, HBC3, exhibited strong activity against Gram-positive bacteria, including MRSA. Genome analysis revealed a unique plasmid encoding two bacteriocin synthesis genes: capidermicin, a class II bacteriocin, and micrococcin P1 (MP1), a thiopeptide. MP1 was first identified in S. capitis. Loss of the plasmid abolished the antibacterial activity. We purified both peptides and evaluated their spectrum of activity. MP1 showed broad activity, especially against Gram-positive cocci, whereas capidermicin was active mainly against Gram-positive rods. These findings demonstrate that S. capitis HBC3 harbors a plasmid encoding two distinct bacteriocins with complementary antibacterial spectra, highlighting the cooperative potential of bacteriocins in combating resistant bacteria.

Indexed as

Anti-Bacterial AgentsBacteriocinsStaphylococcus capitisAntimicrobial PeptidesMethicillin-Resistant Staphylococcus aureusMicrobial Sensitivity TestsPlasmidsAnti-Bacterial AgentsAntimicrobial PeptidesBacteriocinsmicrococcinAntimicrobial peptideBacteriocinCapidermicinMicrococcin P1MRSAStaphylococcus capitis

Identifiers

PMID41620502
PMCPMC12916899

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.